[Webinar] Targeting DNA Damage Repair for Drug Discovery Using the Transcreener ADPR® Assay
Thursday, 04 May 2023
Interested in DNA damage repair pathways for drug discovery? Join us for a live webinar, where Ha Pham, senior scientist at BellBrook Labs, will be sharing her expertise on using the Transcreener ADPR Assay, a biochemical HTS assay, to study enzymes involved in DNA damage repair. She will use CD38 and PARG as target examples
- Published in Emerging Targets, HTS Assays, Innate Immunity
DDX1: A Versatile RNA Helicase
Tuesday, 18 April 2023
DDX1 (Dead-Box Helicase 1) belongs to the DEAD-Box family of ATP-dependent RNA helicases, whose members are collectively involved in almost all aspects of RNA processing: from transcription to remodeling to degradation. They are named for the central Asp-Glu-Ala-Asp (DEAD) sequence they all possess. The 35 human DEAD-Box proteins comprise the largest family of helicases known.
- Published in Emerging Targets, Innate Immunity
Investigating RAB2 as a Vesicle Transporter & Autophagy Initiator
Tuesday, 04 April 2023
RAB2 is part of the RAB family of small GTPases that regulate intracellular trafficking of membrane bound vesicles. It is highly conserved in eukaryotes, from C. elegans to humans. These GTPases influence the creation, movement, attachment, fusion, and destiny of vesicles originating in the endoplasmic reticulum (ER)/Golgi systems. Like other members of its family, RAB2
- Published in Emerging Targets, Innate Immunity
Is PARP1 a Hero or Villain?
Tuesday, 07 March 2023
Not counting histones, PARP1 [Poly(ADP-ribose) Polymerase 1] is the most abundant nuclear protein in mammalian cells. While principally known for its role in various types of DNA repair, recent work expanded it’s repertoire to include genome stability maintenance, chromatin remodeling, DNA methylation/gene expression, cellular differentiation, and cell survival modulation via NAD+/ATP regulation.1 It performs Poly(ADP-ribosyl)ation
- Published in Emerging Targets, Innate Immunity
Advancements in The Ongoing Puzzle to Understand c-SRC
Tuesday, 21 February 2023
Nearly a half-century ago, sequences from the Rous Sarcoma Virus were used to identify the first proto-oncogene and the first of a family of non-receptor tyrosine kinases: c-SRC. Unlike its viral counterpart (v-SRC), c-SRC exists in both an active and inactive state. It is produced in almost every cell type, but expressed highest in the
- Published in Emerging Targets, Innate Immunity
The Challenging Search for BTK Inhibitors
Tuesday, 27 December 2022
Bruton’s Tyrosine Kinase (BTK) is a 76kDa non-receptor Tec kinase that plays numerous diverse roles in B-cell development, immunity, autoimmunity, infection, and cancer. From stem to stern, it consists of an N-terminal plekstrin homology (PH) domain, a TEC homology (TH) domain, two SRC homology (SH2 and SH3) domains, and a C-terminal kinase domain. Unlike SRC,
- Published in Emerging Targets, HTS Assays, Innate Immunity
SARM1 Forefronts Research into Major Neurological Diseases
Monday, 19 December 2022
SARM1 [Sterile alpha & toll/interleukin receptor (TIR) motif-containing protein 1] consists of a N-terminal mitochondrial localization sequence (NLS), an autoinhibitory HEAT/armadillo (ARM) domain, two tandem sterile alpha motif domains (SAMs), and a C-terminal toll/interleukin receptor domain (TIR). It is a human toll like receptor (TLR) adaptor protein. TLR adaptors (MYD88, MAL, TRIF, & TRAM) usually
- Published in Emerging Targets, Innate Immunity, Neurodegenerative Diseases